Students as Surrogates for Managers: Evidence from a Replicated Experiment

Using students as surrogates for managers in experiments is commonplace, yet this practice is not always valid. To explore when the use of student samples is appropriate, we replicate an experiment previously conducted employing a sample of senior managers involved in financial reporting. The result is that although student and manager responses are significantly different from a statistical perspective, both samples lead to the same conclusion for this experiment. The findings suggest that having some disassociation between students and the target population they are meant to represent does not necessarily make them inappropriate surrogates. To examine when inferences are best supported, we explore the comparability for student sub-groups and managers

Performance of the Belle II Silicon Vertex Detector

The Belle II experiment at the SuperKEKB collider of KEK (Japan) will accumulate 50 ab−1 of e+e− collision data at an unprecedented instantaneous luminosity of 8 ×1035 cm−2s−1, about 40 times larger than its predecessor. The Belle II vertex detector plays a crucial role in the rich Belle II physics program, especially for time-dependent measurements. It consists of two layers of DEPFET-based pixels and four layers of double sided silicon strips detectors(SVD). The vertex detector has been recently completed and installed in Belle II for the physics run started in spring 2019. We report here results on the commissioning of the SVD and its performance measured with the first collision data set

The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach

In considering the challenges of approaches to clinical imaging, we are faced with choices that sometimes are impacted by rather dogmatic notions about what is a better or worse technology to achieve the most useful diagnostic image for the patient. For example, is PET or SPECT most useful in imaging any particular disease dissemination? The dictatorial approach would be to choose PET, all other matters being equal. But is such a totalitarian attitude toward imaging selection still valid? In the face of new receptor targeted SPECT agents one must consider the remarkable specificity and sensitivity of these agents. (99m)Tc-Tilmanocept is one of the newest of these agents, now approved for guiding sentinel node biopsy (SLNB) in several solid tumors. Tilmanocept has a Kd of 3×10(-11)M, and it specificity for the CD206 receptor is unlike any other agent to date. This coupled with a number of facts, that specific disease-associated macrophages express this receptor (100 to 150 thousand receptors), that the receptor has multiple binding sites for tilmanocept (>2 sites per receptor) and that these receptors are recycled every 15 min to bind more tilmanocept (acting as intracellular "drug compilers" of tilmanocept into non-degraded vesicles), gives serious pause as to how we select our approaches to diagnostic imaging. Clinically, the size of SLNs varies greatly, some, anatomically, below the machine resolution of SPECT. Yet, with tilmanocept targeting, the SLNs are highly visible with macrophages stably accruing adequate (99m)Tc-tilmanocept counting statistics, as high target-to-background ratios can compensate for spatial resolution blurring. Importantly, it may be targeted imaging agents per se, again such as tilmanocept, which may significantly shrink any perceived chasm between the imaging technologies and anchor the diagnostic considerations in the targeting and specificity of the agent rather than any lingering dogma about the hardware as the basis for imaging approaches. Beyond the elements of imaging applications of these agents is their evolution to therapeutic agents as well, and even in the neo-logical realm of theranostics. Characteristics of agents such as tilmanocept that exploit the natural history of diseases with remarkably high specificity are the expectations for the future of patient- and disease-centered diagnosis and therapy